Apotheca Biosciences Competitors

Apotheca Biosciences (NASDAQ:CBDC) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Apotheca Biosciences and AbCellera Biologics' gross revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Apotheca Biosciences and AbCellera Biologics, as reported by MarketBeat.com.

AbCellera Biologics has a consensus price target of $52.80, suggesting a potential upside of 86.24%. Given AbCellera Biologics' higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than Apotheca Biosciences.

Profitability

This table compares Apotheca Biosciences and AbCellera Biologics' net margins, return on equity and return on assets.

Summary

AbCellera Biologics beats Apotheca Biosciences on 2 of the 2 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and Apotheca Biosciences (NASDAQ:CBDC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares Sana Biotechnology and Apotheca Biosciences' gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sana Biotechnology and Apotheca Biosciences, as reported by MarketBeat.

Sana Biotechnology currently has a consensus target price of $40.00, suggesting a potential upside of 27.47%. Given Sana Biotechnology's higher possible upside, equities research analysts clearly believe Sana Biotechnology is more favorable than Apotheca Biosciences.

Profitability

This table compares Sana Biotechnology and Apotheca Biosciences' net margins, return on equity and return on assets.

Summary

Sana Biotechnology beats Apotheca Biosciences on 2 of the 2 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and Apotheca Biosciences (NASDAQ:CBDC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares Abcam and Apotheca Biosciences' gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Abcam and Apotheca Biosciences, as reported by MarketBeat.

Abcam currently has a consensus target price of $22.00, suggesting a potential upside of 10.61%. Given Abcam's higher possible upside, equities research analysts clearly believe Abcam is more favorable than Apotheca Biosciences.

Profitability

This table compares Abcam and Apotheca Biosciences' net margins, return on equity and return on assets.

Summary

Abcam beats Apotheca Biosciences on 2 of the 2 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Apotheca Biosciences (NASDAQ:CBDC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Seer and Apotheca Biosciences, as reported by MarketBeat.

Seer currently has a consensus target price of $68.00, suggesting a potential upside of 30.79%. Given Seer's higher possible upside, equities research analysts clearly believe Seer is more favorable than Apotheca Biosciences.

Profitability

This table compares Seer and Apotheca Biosciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Seer and Apotheca Biosciences' gross revenue, earnings per share and valuation.

Summary

Seer beats Apotheca Biosciences on 2 of the 2 factors compared between the two stocks.

Apotheca Biosciences (NASDAQ:CBDC) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current recommendations for Apotheca Biosciences and Nuvation Bio, as provided by MarketBeat.com.

Nuvation Bio has a consensus price target of $17.40, suggesting a potential upside of 74.00%. Given Nuvation Bio's higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Apotheca Biosciences.

Profitability

This table compares Apotheca Biosciences and Nuvation Bio's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Apotheca Biosciences and Nuvation Bio's revenue, earnings per share (EPS) and valuation.

Summary

Nuvation Bio beats Apotheca Biosciences on 2 of the 2 factors compared between the two stocks.

Apotheca Biosciences (NASDAQ:CBDC) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current recommendations for Apotheca Biosciences and ImmunityBio, as provided by MarketBeat.com.

ImmunityBio has a consensus price target of $25.00, suggesting a potential upside of 48.19%. Given ImmunityBio's higher possible upside, analysts clearly believe ImmunityBio is more favorable than Apotheca Biosciences.

Profitability

This table compares Apotheca Biosciences and ImmunityBio's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Apotheca Biosciences and ImmunityBio's revenue, earnings per share (EPS) and valuation.

Summary

ImmunityBio beats Apotheca Biosciences on 2 of the 2 factors compared between the two stocks.